Ironwood Pharmaceuticals Inc. announced that its wholly owned subsidiary VectivBio AG has entered into a third amendment to its amended and restated exclusive license agreement with Ferring International Center S.A. Under the amendment, VectivBio will make aggregate payments of $12.5 million to Ferring, with an initial payment of $7.5 million and a second payment of $5 million due by December 31, 2026, subject to certain conditions. The amendment also includes clarifications regarding ownership and certain intellectual property rights. In addition, VectivBio will pay Ferring a high single-digit percentage royalty on net sales of any licensed product for seven years from the first commercial sale, and a low single-digit percentage royalty thereafter until the licensed product is no longer covered by a valid patent claim. The parties have also settled all claims related to litigation in the United States District Court for the Eastern District of Texas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-123974), on December 23, 2025, and is solely responsible for the information contained therein.